Ads
related to: Treatment Macular Degeneration- Wet AMD FAQs
Get Answers To Frequently Asked
Questions About Wet AMD
- Financial Assistance
Learn About Financial Support
That May Be Available To You
- Clinical Study Results
See The Results of A Clinical Study
To Learn More About This Treatment
- Appointment Tips
Get Tips And Useful Information
To Talk to your Retina Specialist
- Wet AMD FAQs
everydayhealth.com has been visited by 10K+ users in the past month
Search results
Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1
Proactive Investors· 5 days agoDrawing from his background in ophthalmology at Johns Hopkins, O'Donnell explained that the drug is...
Earnings call: Lineage Cell Therapeutics reports positive OpRegen trial results
Investing.com· 2 days agoThe therapy showed an average gain in visual acuity, contrasting with the typical loss experienced...
Lineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue Declines
GuruFocus.com via Yahoo Finance· 2 days agoThe company also reported positive long-term data from its OpRegen treatment, showing sustained visual benefits, which underscores the therapys potential in treating geographic ...
EyePoint reports mixed results in diabetic retinopathy trial By Investing.com
Investing.com· 6 days agoEyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) announced interim results from its Phase 2...
STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION
WRBL Columbus· 5 days agoFood and Drug Administration ("FDA") has now determined that its New Drug Application ("NDA") for elamipretide for the treatment of Barth syndrome is entitled to a Priority ...
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
TipRanks via Yahoo Finance· 3 days agoRisk and reward are the yin and yang of stock trading, the two essential yet opposing forces in...
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
Benzinga via Yahoo Finance· 6 days agoOn Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2...
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Zacks via Yahoo Finance· 5 days agoApellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus...
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
GuruFocus.com via Yahoo Finance· 2 days agoIts flagship product, ADVM-022 (Ixo-vec), aims to revolutionize care for patients with wet age-related macular degeneration (AMD) by reducing the frequency ...
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
Benzinga· 6 days agoThe data demonstrated that Duravyu has a biologic effect in patients with NPDR and a favorable safety and tolerability profile; however, the trial did not meet the pre-specified primary endpoint ...
Ad
related to: Treatment Macular Degeneration